MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.53
-0.11 (-0.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.64
Open35.61
Bid35.54 x 1000
Ask36.00 x 200
Day's Range35.40 - 36.02
52 Week Range29.39 - 47.82
Volume2,570,748
Avg. Volume4,367,838
Market Cap18.315B
Beta1.31
PE Ratio (TTM)26.24
EPS (TTM)1.35
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est48.79
Trade prices are not sourced from all markets
  • Mylan Again Defeats Allergan's Efforts to Deny Patients Access to More Affordable Medicine
    PR Newswire12 hours ago

    Mylan Again Defeats Allergan's Efforts to Deny Patients Access to More Affordable Medicine

    HERTFORDSHIRE, England and PITTSBURGH, July 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. Patent Trial and Appeal Board (PTAB), which found that tribal sovereign immunity cannot apply to prevent inter partes review (IPR) proceedings.

  • AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
    Zacks3 days ago

    AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

  • CNBC4 days ago

    Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered

    Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies need to lower the prices they charge.

  • Reuters4 days ago

    Mylan signs U.S. license deal on Humira with AbbVie

    AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. The deal is in line with AbbVie's strategy to fend off rivals of the world's best-selling prescription drug until 2023, giving the company more time to bolster its pipeline with new cash cows to offset the expected sales decline. Humira, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie's net revenue.

  • Reuters7 days ago

    Indivior wins preliminary injunction against generic rival

    A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday. Indivior, a maker of opioid addiction treatments spun-off from Reckitt Benckiser in 2014, has been involved in a number of legal battles with generic drugmakers over their versions of its Suboxone Film . Indivior got a temporary restraining order against Dr.Reddy's in June, but the British firm saw the impact from a generic in the market as Suboxone's market share dropped rapidly by 2.5 percent to 52 percent.

  • Here's Why Marijuana Stock Insys Therapeutics Rose 11% in June
    Motley Fool8 days ago

    Here's Why Marijuana Stock Insys Therapeutics Rose 11% in June

    It's a non-marijuana-based drug that has investors excited this time.

  • Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug
    Bloomberg8 days ago

    Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug

    Bayer AG and Johnson & Johnson won a judge’s ruling that upheld the validity of a patent on the blood-thinning drug Xarelto and will keep Mylan NV from selling a generic, low-cost version until August 2024, when the patent expires. Mylan NV and Sigmapharm Laboratories LLC failed to prove the patent shouldn’t have been issued, U.S. District Court Judge Lawrence Stengel in Wilmington, Delaware, said. The companies can’t sell their generic versions of the drug until the patent expires, the judge said in a separate order.

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch
    PR Newswire12 days ago

    Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch

    HERTFORDSHIRE, England and PITTSBURGH, July 9, 2018 /PRNewswire/ -- Mylan N.V. (MYL) today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon® Patch. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer's disease and the treatment of mild to moderate dementia associated with Parkinson's disease. Mylan President Rajiv Malik said, "The launch of generic Exelon® Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug-delivery systems.

  • Is Mylan N.V. (MYL) a Great Stock for Value Investors?
    Zacks17 days ago

    Is Mylan N.V. (MYL) a Great Stock for Value Investors?

    Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

  • MarketWatch18 days ago

    Adamis has a partner to market its EpiPen competitor after a year-long search

    Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over. The Adamis (ADMP) product, called Symjepi, a syringe that’s filled with the allergic reaction treatment epinephrine, was approved by the U.S. Food and Drug Administration last July and patients have eagerly awaited its release.

  • TheStreet.com19 days ago

    Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

    to make and distribute Adamis' product to treat allergic reactions. EpiPen product, to Novartis' Sandoz Inc. division, which will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, according to a press release from Adamis. As part of the deal, Novartis will pay Adamis an upfront fee and potential future milestone payments, according to a press release.

  • Nordstrom may have trouble, Novartis signs distribution deal, Netflix buys LA billboards
    Yahoo Finance19 days ago

    Nordstrom may have trouble, Novartis signs distribution deal, Netflix buys LA billboards

    Nordstrom, Novartis, Netflix and Dell are the companies to watch.

  • ACCESSWIRE19 days ago

    Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks

    Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Reuters22 days ago

    Indivior gets breather after court extends order blocking generic rival

    Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States. Dr. Reddy's and U.S.-based Mylan NV received approval from the Food and Drug Administration (FDA) earlier this month to launch a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue, forcing the UK company to file an injunction against the decision.

  • Mylan Partners with Lupin to Commercialize Arthritis Biosimilar
    Market Realist22 days ago

    Mylan Partners with Lupin to Commercialize Arthritis Biosimilar

    Today, Mylan (MYL) and Lupin announced that the two companies have entered into a partnership for the commercialization of a biosimilar of Amgen’s (AMGN) Enbrel (etanercept). As per the agreement, Mylan will sell Lupin’s proposed biosimilar of Enbrel in Europe, Latin America, Australia, New Zealand, Africa, and most Asian markets.

  • When Will Mylan Launch Its Recently Approved Generic Suboxone?
    Market Realist23 days ago

    When Will Mylan Launch Its Recently Approved Generic Suboxone?

    Mylan (MYL) received FDA approval for its generic version of Indivior’s (INVVY) opioid addiction treatment drug, Suboxone, on June 14. The FDA also approved Dr. Reddy’s Laboratories’ (RDY) generic version of Suboxone. Dr. Reddy has plans to launch four doses of the drug in the United States.

  • Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
    Zacks23 days ago

    Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel

    Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.

  • Discussing the Prospects of Mylan’s Neulasta Biosimilar
    Market Realist23 days ago

    Discussing the Prospects of Mylan’s Neulasta Biosimilar

    On June 4, Mylan’s (MYL) biosimilar version of Amgen’s (AMGN) Neulasta (pegfilgrastim), Fulphile, received FDA approval. The drug is the first biosimilar of Neulasta approved by the FDA, and it’s expected to be available in the United States.

  • Benzinga23 days ago

    Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 27) Aptinyx Inc (NASDAQ: APTX ) Cardiovascular Systems Inc (NASDAQ: ...

  • A Look at Mylan’s Launch of Its Generic Angiomax Injection
    Market Realist23 days ago

    A Look at Mylan’s Launch of Its Generic Angiomax Injection

    On June 1, Mylan (MYL) announced the launch of a generic version of the Medicines Company’s (MDCO) Angiomax, also known as bivalirudin. The drug is available in injection form in a 250 mg single-dose vial. The drug, which is a direct thrombin inhibitor, is used as an anticoagulant with aspirin.

  • Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar
    PR Newswire23 days ago

    Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar

    MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 /PRNewswire/ -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (MYL) today announced that the two companies will partner to commercialize a biosimilar to Enbrel® (etanercept). Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.

  • How Mylan Stock Has Performed in June
    Market Realist23 days ago

    How Mylan Stock Has Performed in June

    On June 25, Mylan (MYL) ended the trading day at a closing price of $38.11. On the day, MYL stock was trading ~29.7% higher than the 52-week low of $29.39 it reported on August 15, 2017.

  • Discussing Mylan’s Valuation in June: Is the Stock Undervalued?
    Market Realist24 days ago

    Discussing Mylan’s Valuation in June: Is the Stock Undervalued?

    Mylan (MYL) is one of the leading generic pharmaceutical companies in the world. The company offers over 7,000 products and has positioned itself as a global healthcare company that’s registering strong growth in Europe and developing markets.